Cameron Wilson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cameron Wilson has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Alison Jane Yarnall
Newcastle University
2 shared publications - Alison Keogh
University College Dublin
2 shared publications - Jack Lumsdon
Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
2 shared publications - Lynn Rochester
Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE4 5PL, UK
2 shared publications - Marc Tischkowitz
Department of Genomic Medicine, University of Cambridge, Cambridge, UK
2 shared publications - Nichola Fennell
Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
2 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Towards a public-facing version of the CanRisk tool: Co-designing, developing and evaluating MyCanRisk
The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.
- 3 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Open AccessTowards a public-facing version of the CanRisk tool: Co-designing, developing and evaluating MyCanRisk
The CanRisk tool allows healthcare professionals to calculate validated multifactorial estimates of breast, ovarian, and prostate cancer risk. To support patient involvement in risk assessment, we co-designed a public-facing tool, MyCanRisk, which allows patients to collect and share risk information in advance of a clinical appointment, without generating risk estimates. This study describes the user-centred development of MyCanRisk and its initial evaluation. Development involved co-design workshops with patients, public contributors, healthcare professionals, and researchers, followed by iterative accessibility and usability testing against WCAG 2.2. Evaluation used a multi-methods design: 51 women with a family history of breast cancer completed MyCanRisk and, approximately two weeks later, a structured clinical-style interview. Agreement in risk categorisation was assessed using Cohen’s kappa. Semi-structured interviews with a purposive subsample (n=15) explored user experiences. MyCanRisk was perceived as accessible and easy to use. Agreement between MyCanRisk and structured interviews for risk categorisation was substantial (κ = 0.81, 95% CI 0.65–0.97). Discrepancies mainly reflected difficulties recalling detailed family history, such as ages at diagnosis and dates of birth/death. Participants valued the stepwise flow and asynchronous completion but reported challenges when their knowledge was incomplete. Suggested improvements included options to record approximate or unknown data and greater flexibility to update submissions. MyCanRisk has the potential to reduce data collection burden during clinical encounters, support patient preparation for risk assessment, and streamline cancer risk assessment pathways. With further refinement and testing in more diverse populations, it may facilitate earlier identification of individuals at increased cancer risk.
- Open Access
- 30 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e98987
Acceptability of Wearable Digital Devices for Remote Continuous Mobility Monitoring in People With Parkinson Disease and Carers: Qualitative Study
Background: Parkinson disease (PD) impairs mobility and motor function, making accurate mobility assessment important for effective management and treatment planning. Traditional clinical assessments often rely on periodic clinical evaluations, which may not capture day-to-day symptom fluctuations. Wearable devices offer a promising alternative with continuous, objective tracking of mobility (eg, gait). However, although these tools provide valuable insights for patients and clinicians, their successful implementation depends on their acceptability to users. Objective: This study aimed to explore the acceptability of wearable devices for remote continuous mobility monitoring in PD from the perspectives of people with PD and informal carers. Methods: This international qualitative study used purposive sampling to recruit a diverse sample of 72 people with PD and 20 informal carers from the United Kingdom, Ireland, Belgium, Germany, Spain, and the United States. Participants were recruited between June 2023 and February 2026 through multiple community-based routes. One-to-one semistructured interviews, conducted online, via telephone, or in person, explored views on wearable devices for digital mobility assessment. Interview data were analyzed using Braun and Clarke’s 6-phase reflexive thematic analysis. Results: Most people with PD were generally open to wearable monitoring when it could capture motor fluctuations between “on” and “off” periods that were difficult to convey during clinical appointments, reduce reliance on memory, provide objective evidence to support treatment and medication discussions and self-advocacy, and track changes in mobility over time, which some felt could be reassuring. Acceptability depended on devices having a clear purpose, requiring minimal effort, and being easy to use. Tremor, reduced dexterity, and “off” periods could make fastening straps, navigating menus, and charging devices difficult. Carers valued wearable monitoring for the reassurance and safety it offered, particularly fall detection, and for support with both clinical and everyday decision-making but emphasized that devices must operate passively and integrate into daily caregiving without adding burden. Conclusions: Wearable mobility monitoring was generally acceptable to people with PD and carers when it offered clear clinical value, fit easily into everyday life, and provided reassurance that remote monitoring would complement rather than replace clinical care. As PD mobility was experienced as a shared concern within the care relationship, the value of monitoring depended on how well it supported the wider care dyad rather than the person with PD alone. These findings suggest that successful implementation will require co-design with people with PD and carers, alongside thoughtful clinical integration, to ensure that wearable technologies are both acceptable and effective in practice.
- 30 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e98987
Open AccessAcceptability of Wearable Digital Devices for Remote Continuous Mobility Monitoring in People With Parkinson Disease and Carers: Qualitative Study
Background: Parkinson disease (PD) impairs mobility and motor function, making accurate mobility assessment important for effective management and treatment planning. Traditional clinical assessments often rely on periodic clinical evaluations, which may not capture day-to-day symptom fluctuations. Wearable devices offer a promising alternative with continuous, objective tracking of mobility (eg, gait). However, although these tools provide valuable insights for patients and clinicians, their successful implementation depends on their acceptability to users. Objective: This study aimed to explore the acceptability of wearable devices for remote continuous mobility monitoring in PD from the perspectives of people with PD and informal carers. Methods: This international qualitative study used purposive sampling to recruit a diverse sample of 72 people with PD and 20 informal carers from the United Kingdom, Ireland, Belgium, Germany, Spain, and the United States. Participants were recruited between June 2023 and February 2026 through multiple community-based routes. One-to-one semistructured interviews, conducted online, via telephone, or in person, explored views on wearable devices for digital mobility assessment. Interview data were analyzed using Braun and Clarke’s 6-phase reflexive thematic analysis. Results: Most people with PD were generally open to wearable monitoring when it could capture motor fluctuations between “on” and “off” periods that were difficult to convey during clinical appointments, reduce reliance on memory, provide objective evidence to support treatment and medication discussions and self-advocacy, and track changes in mobility over time, which some felt could be reassuring. Acceptability depended on devices having a clear purpose, requiring minimal effort, and being easy to use. Tremor, reduced dexterity, and “off” periods could make fastening straps, navigating menus, and charging devices difficult. Carers valued wearable monitoring for the reassurance and safety it offered, particularly fall detection, and for support with both clinical and everyday decision-making but emphasized that devices must operate passively and integrate into daily caregiving without adding burden. Conclusions: Wearable mobility monitoring was generally acceptable to people with PD and carers when it offered clear clinical value, fit easily into everyday life, and provided reassurance that remote monitoring would complement rather than replace clinical care. As PD mobility was experienced as a shared concern within the care relationship, the value of monitoring depended on how well it supported the wider care dyad rather than the person with PD alone. These findings suggest that successful implementation will require co-design with people with PD and carers, alongside thoughtful clinical integration, to ensure that wearable technologies are both acceptable and effective in practice.
- Open Access
- 6 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 85
Experiences of implementation of personalised risk estimates for breast cancer in clinical practice: a systematic review and qualitative synthesis
Breast cancer risk prediction tools are increasingly used in clinical practice to guide early detection, prevention, and shared decision-making. Unlike population-level screening, personalised risk estimates incorporate individual factors (family history, genetics, lifestyle, breast density), providing tailored assessments. These tools show promise for improving patient engagement and targeted prevention, but require effective implementation to ensure they enhance rather than complicate care. This review explores healthcare professionals’ experiences with providing personalised breast cancer risk estimates and women’s experiences of receiving them in clinical settings. Four online databases were searched for qualitative studies on the use of personalised risk estimates in clinical practice. Data were analysed using inductive thematic analysis. Seven papers were included; the majority based in the UK screening setting. Most used interview and focus-groups, with thematic analysis. Both healthcare professionals and women expressed high acceptance of personalised risk estimates. Women found the information empowering and useful for future health planning. Effective communication and prompt follow-up from healthcare professionals were crucial for positive experiences. Professionals highlighted challenges in implementation, including the need for additional healthcare professionals, safe care pathways, and technology. The studies focused on stratified breast screening, raising questions about offering less frequent screening to lower-risk women. This approach must be supported by strong evidence, and women should retain choice in screening intervals. Personalised risk estimates are favourably viewed in clinical practice, but studies mainly examined research settings. Further research is needed to understand real-world implementation, identify barriers, and optimise use across diverse clinical environments.
- 6 July 2026
- Published by Springer Nature in Journal of Community Genetics
- Vol. 17 (4) , 85
Open AccessExperiences of implementation of personalised risk estimates for breast cancer in clinical practice: a systematic review and qualitative synthesis
Breast cancer risk prediction tools are increasingly used in clinical practice to guide early detection, prevention, and shared decision-making. Unlike population-level screening, personalised risk estimates incorporate individual factors (family history, genetics, lifestyle, breast density), providing tailored assessments. These tools show promise for improving patient engagement and targeted prevention, but require effective implementation to ensure they enhance rather than complicate care. This review explores healthcare professionals’ experiences with providing personalised breast cancer risk estimates and women’s experiences of receiving them in clinical settings. Four online databases were searched for qualitative studies on the use of personalised risk estimates in clinical practice. Data were analysed using inductive thematic analysis. Seven papers were included; the majority based in the UK screening setting. Most used interview and focus-groups, with thematic analysis. Both healthcare professionals and women expressed high acceptance of personalised risk estimates. Women found the information empowering and useful for future health planning. Effective communication and prompt follow-up from healthcare professionals were crucial for positive experiences. Professionals highlighted challenges in implementation, including the need for additional healthcare professionals, safe care pathways, and technology. The studies focused on stratified breast screening, raising questions about offering less frequent screening to lower-risk women. This approach must be supported by strong evidence, and women should retain choice in screening intervals. Personalised risk estimates are favourably viewed in clinical practice, but studies mainly examined research settings. Further research is needed to understand real-world implementation, identify barriers, and optimise use across diverse clinical environments.
- Open Access
- 9 May 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e68782
Cocreating the Visualization of Digital Mobility Outcomes: Delphi-Type Process With Patients
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients’ data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process.
- 9 May 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9 (1) , e68782
Open AccessCocreating the Visualization of Digital Mobility Outcomes: Delphi-Type Process With Patients
Background: Recent technological advances in wearable devices offer new potential for measuring mobility in real-world contexts. Mobilise-D has validated digital mobility outcomes to provide novel outcomes and end points in clinical research of 4 different long-term health conditions (Parkinson disease, multiple sclerosis, chronic obstructive pulmonary disease, and proximal femoral fracture). These outcomes also provide unique information that is important to patients; however, there is limited literature that explores the optimal methods to achieve this, such as the best way to visualize patients’ data. Objective: This study aimed to identify meaningful outcomes for each condition and how to best visualize them from the perspective of end users. Methods: Using a Delphi-type protocol with patients as subject matter experts, we gathered iterative feedback on the cocreation of visualizations through 3 rounds of questionnaires. An open-ended questionnaire was used in round 1 to understand what aspects of mobility were most influenced by their health condition. These responses were mapped onto relevant digital mobility outcomes and walking experiences and then prioritized for visualization. Using patient responses, we worked alongside researchers, clinicians, and a patient advisory group to develop visualizations that depicted a week of mobility data. During rounds 2 and 3, participants rated usefulness and ease of understanding on a 5-point Likert scale and provided unstructured feedback in comment boxes for each visualization. Visualizations were refined using the feedback from round 2 before receiving further feedback in round 3. Results: Participation varied across rounds 1 to 3 (n=48, n=79, and n=78, respectively). Round 1 identified important outcomes and contexts for each health condition, such as walking speed and stride length for people with Parkinson disease or multiple sclerosis and number of steps for people with chronic obstructive pulmonary disease or proximal femoral fracture. The consensus was not reached for any visualization reviewed in round 2 or 3. Feedback was generally positive, and some participants reported that they were able to understand the visualization and interpret what the visualization represented. Conclusions: Through the feedback provided and existing data visualization principles, we developed recommendations for future visualizations of mobility- and health-related data. Visualizations should be readable by ensuring that large and clear fonts are used and should be friendly for people with vision impairments, such as color blindness. Patients have a strong understanding of their own condition and its variability; hence, adding additional factors into visualizations is recommended to better reflect the nuances of a condition. Ensuring that outcomes and visualizations are meaningful requires close collaboration with patients throughout the development process.